The 229 pill most commonly refers to the prescription combination tablet containing Oxycodone Hydrochloride (7.5 mg) and Acetaminophen (325 mg), manufactured for Alvogen. It is a potent semi-synthetic opioid analgesic and non-opioid antipyretic/analgesic fixed-dose combination, classified as a Schedule II controlled substance in the United States due to significant risks of misuse, dependence, and overdose.
Pill Identification & Physical Characteristics
Property – Description
- Active Ingredients – Oxycodone Hydrochloride (7.5 mg) & Acetaminophen (325 mg)
- Imprint –
229debossed on one side; Alvogen logo (or dual-triangle shape) on the reverse - Shape & Color – Round; Orange to Yellow-Orange
- Drug Class – Opioid Agonist / Non-Opioid Analgesic Combination
- Distributor / Manufacturer – Alvogen / Packaging Partners
- (Note: Other less common tablets bearing the number “229” include white round Trazodone 100 mg tablets or Ethinyl Estradiol/Norgestimate tablets. Color, shape, and reverse markings are critical to confirming identity.)
Mechanism of Action
The formulation operates via two distinct, complementary pathways to produce synergistic analgesia:
- Oxycodone Component (Opioid Agonist): Binds selectively to central nervous system (CNS) opioid receptors. This inhibits the release of nociceptive neurotransmitters (such as substance P and glutamate) from primary sensory afferents, activates descending inhibitory pain pathways, and alters the emotional perception of pain in higher brain centers.
- Acetaminophen Component (APAP): Acts primarily in the CNS to inhibit prostaglandin synthesis (via central COX inhibition) and modulates serotonergic inhibitory pathways and the endocannabinoid system. It provides baseline analgesia and antipyresis without significant peripheral anti-inflammatory effects.
Indications & Dosage
Clinical Indications
- Indicated for the management of acute, moderate-to-severe pain where alternative non-opioid treatments have proved ineffective, poorly tolerated, or inadequate.
General Adult Dosing
- Standard Adult Dosing: 1 tablet orally every 4 to 6 hours as needed for pain.
- Maximum Daily Limits:
- Acetaminophen Ceiling: Total daily intake of acetaminophen from all sources (including OTC cold/pain medicines) must not exceed 4,000 mg in 24 hours (and often capped at 3,000 mg/day in clinical practice to prevent hepatotoxicity).
- Oxycodone Titration: Should be prescribed at the lowest effective dose for the shortest duration necessary.
- Administration: Swallow whole with a full glass of water. It can be taken with or without food, though taking it with meals may reduce gastrointestinal discomfort.
Side Effects
Common Adverse Reactions
- Drowsiness, sedation, lightheadedness, and dizziness
- Nausea, vomiting, and abdominal cramping
- Constipation and dry mouth
- Sweating (diaphoresis) and mild pruritus (itching)
Severe & Emergent Adverse Reactions
- Life-Threatening Respiratory Depression: Abnormally slow, shallow, or irregular breathing.
- Acute Hepatotoxicity: Liver injury or acute liver failure caused by acetaminophen overdose.
- Severe Hypotension & Bradycardia: Significant drops in blood pressure and syncope (fainting).
- Adrenal Insufficiency: Chronic opioid use can suppress hypothalamic-pituitary-adrenal axis function.
- Severe Cutaneous Adverse Reactions (SCARs): Rare but severe acetaminophen skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis).
Precautions & Drug Interactions
- Central Nervous System Depressants: Concurrent administration with benzodiazepines, other sedatives, hypnotics, tranquilizers, or alcohol creates severe additive CNS depression, leading to profound sedation, coma, or fatal respiratory arrest.
- Hepatotoxic Agents: Avoid concurrent use with any other medications containing acetaminophen (APAP), as well as chronic heavy alcohol consumption, due to the risk of irreversible liver failure.
- CYP3A4 and CYP2D6 Inhibitors/Inducers: Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase oxycodone plasma concentrations to dangerous levels, while CYP3A4 inducers (e.g., carbamazepine, rifampin) can reduce efficacy or precipitate withdrawal.
- Respiratory Conditions: Contraindicated in patients with severe respiratory depression, acute or severe bronchial asthma in unmonitored settings, or hypercarbia.
- Gastrointestinal Obstruction: Contraindicated in known or suspected mechanical bowel obstruction or paralytic ileus.
Black Box Warnings
- Critical Safety Warnings:
- Hepatotoxicity: Acetaminophen is linked to acute liver failure, sometimes resulting in liver transplantation or death, primarily associated with doses exceeding 4,000 mg/day.
- Addiction, Abuse, and Misuse: Carries high risk of opioid use disorder, overdose, and death even when used as directed.
- Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or dose escalation.
- Concomitant Use with Benzodiazepines or CNS Depressants: Profound sedation, respiratory depression, coma, and death may result from co-use with sedatives or alcohol.
- Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged use during pregnancy can result in life-threatening withdrawal symptoms in the newborn.
- Accidental Pediatric Ingestion: Even a single dose accidentally ingested by a child can cause fatal respiratory arrest. >